Tobias Moser, Fabian Foettinger, Wolfgang Hitzl, Bianka Novotna, Thomas Berger, Gabriel Bsteh, Franziska Di Pauli, Harald Hegen, Barbara Kornek, Dieter Langenscheidt, Johann Sellner
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study
Annals of clinical and translational neurology
followup care incidental findings ifs trauma computed tomography scans component comprehensive healthcare objective assess effectiveness predischarge disclosure practice guideline identify factors contributing followup failure secondary analysis prospective observational database 615 patients ifs november 2019 february 2020 followup compliance determined electronic medical record review andor telephone call mailout request voluntary participation volunteers answered predetermined questionnaire regarding followup care total 115 patients 19 computed tomographybased ifs recommending additional imaging followups seventyfour 64 patients lost inclusion result death 121 inability contact 513 noninterest 52 remaining 36 patients 19 received followup care 527 17 472 statistical differences existed among groups age sex mechanism injury glasgow coma scale score whether informed physicians midlevel providers type total 15 88 nonfollowup patients recall disclosure discharge paperwork instructions 19 compliant patients 9 additional imaging 5 biopsies andor surgical intervention n 3 cancer n 2 benign 3 primary care advice additional studies 2 referred specialists predischarge disclosure ifs contribute significantly overall patient health nonetheless fewer half patients pursue followup recommendations often citing failure recall verbalwritten instructions effective communication attention health literacy followup telephone calls postdischarge appointments potential catalysts improved patient compliance